Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Depreciation and Depletion (2022 - 2025)

Inhibikase Therapeutics (IKT) has 4 years of Depreciation and Depletion data on record, last reported at $23688.0 in Q3 2025.

  • On a quarterly basis, Depreciation and Depletion rose 260.66% to $23688.0 in Q3 2025 year-over-year; TTM through Mar 2026 was $47845.0, a 47.86% increase, with the full-year FY2025 number at $60499.0, up 130.28% from a year prior.
  • Depreciation and Depletion reached $23688.0 in Q3 2025 per IKT's latest filing, down from $24157.0 in the prior quarter.
  • Over the last five years, Depreciation and Depletion for IKT hit a ceiling of $159204.0 in Q2 2023 and a floor of $1681.0 in Q3 2022.
  • A 4-year average of $20836.7 and a median of $6568.0 in 2023 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: skyrocketed 290.72% in 2023, then tumbled 95.87% in 2024.
  • Tracing IKT's Depreciation and Depletion over 4 years: stood at $5042.0 in 2022, then soared by 30.27% to $6568.0 in 2023, then fell by 0.02% to $6567.0 in 2024, then skyrocketed by 260.71% to $23688.0 in 2025.
  • Business Quant data shows Depreciation and Depletion for IKT at $23688.0 in Q3 2025, $24157.0 in Q2 2025, and $12654.0 in Q1 2025.